Literature DB >> 27265680

A Comprehensive Investigation toward the Indicative Proteins of Bladder Cancer in Urine: From Surveying Cell Secretomes to Verifying Urine Proteins.

Jiao Guo1,2, Yan Ren3, Guixue Hou1,2, Bo Wen3, Feng Xian1,2, Zhen Chen1, Ping Cui1, Yingying Xie1,2, Jin Zi3, Liang Lin3, Song Wu4, Zesong Li4, Lin Wu1,2, Xiaomin Lou1,2, Siqi Liu1,2,3.   

Abstract

Urine is an ideal material to study the cancer-related protein biomarkers in bladder, whereas exploration to these candidates is confronting technique challenges. Herein, we propose a comprehensive strategy of searching the urine proteins related with bladder cancer. The strategy consists of three core combinations, screening the biomarker candidates in the secreted proteins derived from the bladder cancer cell lines and verifying them in patient urines, defining the differential proteins through two-dimensional electrophoresis (2DE) and isobaric tags for relative and absolute quantitation (iTRAQ) coupled with LC-MS/MS, and implementing quantitative proteomics of profiling and targeting analysis. With proteomic survey, a total of 700 proteins were found with their abundance of secreted proteins in cancer cell lines different from normal, while 87 proteins were identified in the urine samples. The multiple reaction monitoring (MRM)-based quantification was adapted in verifying the bladder cancer related proteins in individual urine samples, resulting in 10 differential urine proteins linked with the cancer. Of these candidates, receiver operating characteristic analysis revealed that the combination of CO3 and LDHB was more sensitive as the cancer indicator than other groups. The discovery of the bladder cancer indicators through our strategy has paved an avenue to further biomarker validation.

Entities:  

Keywords:  2DE; MRM; biomarker; bladder cancer; iTRAQ; urine

Mesh:

Substances:

Year:  2016        PMID: 27265680     DOI: 10.1021/acs.jproteome.6b00106

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  4 in total

1.  Detecting Modifications in Proteomics Experiments with Param-Medic.

Authors:  Damon H May; Kaipo Tamura; William S Noble
Journal:  J Proteome Res       Date:  2019-03-05       Impact factor: 4.466

2.  Three-Dimensionally Functionalized Reverse Phase Glycoprotein Array for Cancer Biomarker Discovery and Validation.

Authors:  Li Pan; Hillary Andaluz Aguilar; Linna Wang; Anton Iliuk; W Andy Tao
Journal:  J Am Chem Soc       Date:  2016-11-17       Impact factor: 15.419

Review 3.  Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application.

Authors:  Rongrong Huang; Zhongsi Chen; Lei He; Nongyue He; Zhijiang Xi; Zhiyang Li; Yan Deng; Xin Zeng
Journal:  Theranostics       Date:  2017-08-18       Impact factor: 11.556

4.  Distinct gut metagenomics and metaproteomics signatures in prediabetics and treatment-naïve type 2 diabetics.

Authors:  Huanzi Zhong; Huahui Ren; Yan Lu; Chao Fang; Guixue Hou; Ziyi Yang; Bing Chen; Fangming Yang; Yue Zhao; Zhun Shi; Baojin Zhou; Jiegen Wu; Hua Zou; Jin Zi; Jiayu Chen; Xiao Bao; Yihe Hu; Yan Gao; Jun Zhang; Xun Xu; Yong Hou; Huanming Yang; Jian Wang; Siqi Liu; Huijue Jia; Lise Madsen; Susanne Brix; Karsten Kristiansen; Fang Liu; Junhua Li
Journal:  EBioMedicine       Date:  2019-09-03       Impact factor: 8.143

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.